Eguia A, Bagan L, Cardona F. Review and update on drugs related to the development of osteonecrosis of the jaw. Med Oral Patol Oral Cir Bucal. 2020 Jan 1;25 (1):e71-83.
doi:10.4317/medoral.23191
http://dx.doi.org/doi:10.4317/medoral.23191
1.
Marx RE. Pamidronate (Aredia) and Zoledronate (Zometa) induced
avascular necrosis of the jaws: a growing epidemic. J Oral
Maxillofac Surg.
2003;61:1115-7. |
|
|||
|
||||
2.
Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis
of the jaws associated with the use of Bisphosphonates: a review
of 63 cases. J Oral Maxillofac Surg.
2004;62:527-34. |
|
|||
|
||||
3.
Bagan JV, Murillo J, Jimenez Y, Poveda R, Milian MA, Sanchis JM,
et al. Cancer chemotherapy induced avascular jaw osteonecrosis:
series of 10 cases. J Oral Pathol Med.
2005;34:120-3. |
|
|||
|
||||
4.
McGowan K, McGowan T, Ivanovski S. Risk factors for
medication-related osteonecrosis of the jaws: A systematic review.
Oral Dis.
2018;24:527-536. |
|
|||
|
||||
5.
Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related
osteonecrosis of the jaw: background and guidelines for diagnosis,
staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol
Endod.
2006;102:433-41. |
|
|||
|
||||
6.
McMahon RE, Bouquot JE, Glueck CJ, Griep JA, Adams WR, Spolnik KJ,
et al. Staging bisphosphonate-related osteonecrosis of the jaw
should include early stages of disease. J Oral Maxillofac Surg.
2007;65:1899-900. |
|
|||
|
||||
7.
Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra
B, et al. American Association of Oral and Maxillofacial Surgeons
position paper on bisphosphonate-related osteonecrosis of the jaw
- 2009 update. J Oral Maxillofac Surg.
2009;67:2-12. |
|
|||
|
||||
8.
Mawardi H, Treister N, Richardson P, Anderson K, Munshi N, Faiella
RA, et al. Sinus tracts-an early sign of bisphosphonate associated
osteonecrosis of the jaws?. J Oral Maxillofac Surg.
2009;67:593-601. |
|
|||
|
||||
9.
Bagan JV, Jimenez Y, Diaz JM, Murillo J, Sanchis JM, Poveda R, et
al. Osteonecrosis of the jaws in intravenous bisphosphonate use:
proposal for a modification of the clinical classification. Oral
Oncol.
2009;45:645-6. |
|
|||
|
||||
10.
Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, et
al. Bisphosphonate-related osteonecrosis of the jaw: position
paper from the Allied Task Force Committee of Japanese Society for
Bone and Mineral Research, Japan Osteoporosis Society, Japanese
Society of Periodontology, Japanese Society for Oral and
Maxillofacial Radiology, and Japanese Society of Oral and
Maxillofacial Surgeons. J Bone Miner Metab.
2010;28:365-83. |
|
|||
|
||||
11.
Bagan JV, Hens-Aumente E, Leopoldo-Rodado M, Poveda-Roda R, Bagan
L. Bisphosphonate-related osteonecrosis of the jaws: study of the
staging system in a series of clinical cases. Oral Oncol.
2012;48:753-7. |
|
|||
|
||||
12.
Bedogni A, Fusco V, Agrillo A, Campisi G. Learning from
experience. Proposal of a refined definition and staging system
for bisphosphonate-related osteonecrosis of the jaw (BRONJ). Oral
Dis.
2012;18:621-3. |
|
|||
|
||||
13.
Patel S, Choyee S, Uyanne J, Nguyen AL, Lee P, Sedghizadeh PP, et
al. Non-exposed bisphosphonate-related osteonecrosis of the jaw: a
critical assessment of current definition, staging, and treatment
guidelines. Oral Dis.
2012;18:625-32. |
|
|||
|
||||
14.
Schiodt M, Reibel J, Oturai P, Kofod T. Comparison of nonexposed
and exposed bisphosphonate-induced osteonecrosis of the jaws: a
retrospective analysis from the Copenhagen cohort and a proposal
for an updated classification system. Oral Surg Oral Med Oral
Pathol Oral Radiol.
2014;117:204-13. |
|
|||
|
||||
15.
Franco S, Miccoli S, Limongelli L, Tempesta A, Favia G, Maiorano
E, et al. New dimensional staging of bisphosphonate-related
osteonecrosis of the jaw allowing a guided surgical treatment
protocol: long-term follow-up of 266 lesions in neoplastic and
osteoporotic patients from the university of bari. Int J Dent.
2014;2014:935657. |
|
|||
|
||||
16.
Mawardi H, Woo SB. Medication-related osteonecrosis of the jaws,
stage 0--do we need stage 0 any more?. J Oral Maxillofac Surg.
2015;73:797-7. |
|
|||
|
||||
17.
Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, et
al. Antiresorptive agent-related osteonecrosis of the jaw:
Position Paper 2017 of the Japanese Allied Committee on
Osteonecrosis of the Jaw. Japanese Allied Committee on
Osteonecrosis of the Jaw. J Bone Miner Metab.
2017;35:6-19. |
|
|||
|
||||
18.
Otto S, Pautke C, Van den Wyngaert T, Niepel D, Schiødt M.
Medication-related osteonecrosis of the jaw: Prevention, diagnosis
and management in patients with cancer and bone metastases. Cancer
Treat Rev.
2018;69:177-87. |
|
|||
|
||||
19.
Jacobsen C, Zemann W, Obwegeser JA, Grätz KW, Metzler P. The
phosphorous necrosis of the jaws and what can we learn from the
past: a comparison of "phossy" and "bisphossy"
jaw. Oral Maxillofac Surg.
2014;18:31-7. |
|
|||
|
||||
20.
Pollock RA, Brown TW Jr, Rubin DM. "Phossy Jaw" and
"Bis-phossy Jaw" of the 19th and the 21st Centuries: The
Diuturnity of John Walker and the Friction Match. Craniomaxillofac
Trauma Reconstr.
2015;8:262-70. |
|
|||
|
||||
21.
Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra
B, et al. American Association of Oral and Maxillofacial Surgeons.
American Association of Oral and Maxillofacial Surgeons position
paper on medication-related osteonecrosis of the jaw--2014 update.
J Oral Maxillofac Surg.
2014;72:1938-56. |
|
|||
|
||||
22.
Khan AA, Morrison A, Kendler DL, Rizzoli R, Hanley DA, Felsenberg
D, et al. Case-Based Review of Osteonecrosis of the Jaw (ONJ) and
Application of the International Recommendations for Management
From the International Task Force on ONJ. J Clin Densitom.
2017;20:8-24. |
|
|||
|
||||
23.
Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan
F, et al. Diagnosis and management of osteonecrosis of the jaw: a
systematic review and international consensus. J Bone Miner Res.
2015;30:3-23. |
|
|||
|
||||
24. Yeo AC, Lye KW, Poon CY. Bisphosphonate-related osteonecrosis of the jaws. Singapore Dent J. 2005;27:36-40. |
|
|||
|
||||
25.
Taylor KH, Middlefell LS, Mizen KD. Osteonecrosis of the jaws
induced by anti-RANK ligand therapy. Br J Oral Maxillofac Surg.
2010;48:221-3. |
|
|||
|
||||
26.
Van Poznak C. Osteonecrosis of the jaw and bevacizumab therapy.
Breast Cancer Res Treat.
2010;122:189-91. |
|
|||
|
||||
27.
Brunello A, Saia G, Bedogni A, Scaglione D, Basso U. Worsening of
osteonecrosis of the jaw during treatment with sunitinib in a
patient with metastatic renal cell carcinoma. Bone.
2009;44:173-5. |
|
|||
|
||||
28.
Beth-Tasdogan NH, Mayer B, Hussein H, Zolk O. Interventions for
managing medication-related osteonecrosis of the jaw. Cochrane
Database Syst Rev.
2017;10:CD012432. |
|
|||
|
||||
29.
Tai TW, Su FC, Chen CY, Jou IM, Lin CF. Activation of p38
MAPK-regulated Bcl-xL signaling increases survival against
zoledronic acid-induced apoptosis in osteoclast precursors. Bone.
2014;67:166-74. |
|
|||
|
||||
30.
Quispe D, Shi R, Burton G. Osteonecrosis of the jaw in patients
with metastatic breast cancer: ethnic and socio-economic aspects.
Breast J.
2011;17:510-3. |
|
|||
|
||||
31.
Hamadeh IS, Ngwa BA, Gong Y. Drug induced osteonecrosis of the
jaw. Cancer Treat Rev.
2015;41:455-64. |
|
|||
|
||||
32.
Lo JC, O'Ryan FS, Gordon NP, Yang J, Hui RL, Martin D, et al.
Prevalence of osteonecrosis of the jaw in patients with oral
bisphosphonate exposure. J Oral Maxillofac Surg.
2010;68:243-53. |
|
|||
|
||||
33.
Krstevska S, Stavric SG, Cevrevska L, Georgjievski B, Karanfilski
O, Sotirova T, et al. Osteonecrosis of the Jaw After
Bisphosphonates Treatment in Patients with Multiple Myeloma. Med
Arch.
2015;69:367-70. |
|
|||
|
||||
34.
Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S,
Andreadis CG, et al. Longitudinal cohort study of risk factors in
cancer patients of bisphosphonate-related osteonecrosis of the
jaw. J Clin Oncol.
2009;27:5356-62. |
|
|||
|
||||
35.
Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G.
Bisphosphonate-induced osteonecrosis of the jaws: prospective
study of 80 patients with multiple myeloma and other malignancies.
Oral Oncol.
2008;44:857-69. |
|
|||
|
||||
36.
Qi WX, Tang LN, He AN, Yao Y, Shen Z. Risk of osteonecrosis of the
jaw in cancer patients receiving denosumab: a meta-analysis of
seven randomized controlled trials. Int J Clin Oncol.
2014;19:403-10. |
|
|||
|
||||
37.
Mauri D, Valachis A, Polyzos IP, Polyzos NP, Kamposioras K, Pesce
LL. Osteonecrosis of the jaw and use of bisphosphonates in
adjuvant breast cancer treatment: a meta-analysis. Breast Cancer
Res Treat.
2009;116:433-9. |
|
|||
|
||||
38.
Deeks ED. Denosumab: A Review in Postmenopausal Osteoporosis.
Drugs Aging.
2018;35:163-73. |
|
|||
|
||||
39.
Iranikhah M, Deas C, Murphy P, Freeman MK. Effects of Denosumab
After Treatment Discontinuation: A Review of the Literature.
Consult Pharm.
2018;33:142-51. |
|
|||
|
||||
40.
Aljohani S, Gaudin R, Weiser J, Tröltzsch M, Ehrenfeld M,
Kaeppler G, et al. Osteonecrosis of the jaw in patients treated
with denosumab: A multicenter case series. J Craniomaxillofac
Surg.
2018;46:1515-25. |
|
|||
|
||||
41.
Baron R, Ferrari S, Russell RG. Denosumab and bisphosphonates:
different mechanisms of action and effects. Bone.
2011;48:677-92. |
|
|||
|
||||
42.
Papapoulos S, Chapurlat R, Libanati C, Brandi ML, Brown JP,
Czerwiński E, et al. Five years of denosumab exposure in women
with postmenopausal osteoporosis: results from the first two years
of the FREEDOM extension. J Bone Miner Res.
2012;27:694-701. |
|
|||
|
||||
43.
Mander KA, Finnie JW. Tumor angiogenesis, anti-angiogenic therapy
and chemotherapeutic resistance. Aust Vet J.
2018;96:371-8. |
|
|||
|
||||
44.
Pimolbutr K, Porter S, Fedele S. Osteonecrosis of the Jaw
Associated with Antiangiogenics in Antiresorptive-Naïve Patient:
A Comprehensive Review of the Literature. Biomed Res Int.
2018;2018:8071579. |
|
|||
|
||||
45.
Chang J, Hakam AE, McCauley LK. Current Understanding of the
Pathophysiology of Osteonecrosis of the Jaw. Curr Osteoporos Rep.
2018;16:584-95. |
|
|||
|
||||
46.
Aldridge SE, Lennard TW, Williams JR, Birch MA. Vascular
endothelial growth factor receptors in osteoclast differentiation
and function. Biochem Biophys Res Commun.
2005;335:793-8. |
|
|||
|
||||
47.
Pazianas M. Osteonecrosis of the jaw and the role of macrophages.
J Natl Cancer Inst.
2011;103:232-40. |
|
|||
|
||||
48.
Zarringhalam P, Brizman E, Shakib K. Medication-related
osteonecrosis of the jaw associated with aflibercept. Br J Oral
Maxillofac Surg.
2017;55:314-5. |
|
|||
|
||||
49.
Won AM, Boddu P, Otun AO, Aponte-Wesson R, Chambers M. Chronic
myelogenous leukemia presenting with osteonecrosis of the jaw as a
rare but debilitating toxicity of dasatinib: a case report and
literature review. Oral Surg Oral Med Oral Pathol Oral Radiol.
2018;126:e208-11. |
|
|||
|
||||
50.
Abel Mahedi Mohamed H, Nielsen CEN, Schiodt M. Medication related
osteonecrosis of the jaws associated with targeted therapy as
monotherapy and in combination with antiresorptives. A report of 7
cases from the Copenhagen Cohort. Oral Surg Oral Med Oral Pathol
Oral Radiol.
2018;125:157-63. |
|
|||
|
||||
51.
Viviano M, Rossi M, Cocca S. A rare case of osteonecrosis of the
jaw related to imatinib. J Korean Assoc Oral Maxillofac Surg.
2017;43:120-4. |
|
|||
|
||||
52.
Patel V, Sproat C, Kwok J, Tanna N. Axitinib-related osteonecrosis
of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol.
2017;124:e257-60. |
|
|||
|
||||
53.
Garuti F, Camelli V, Spinardi L, Bucci L, Trevisani F.
Osteonecrosis of the jaw during sorafenib therapy for
hepatocellular carcinoma. Tumori. 2016;102(Suppl.
2). |
|
|||
|
||||
54.
Marino R, Orlandi F, Arecco F, Gandolfo S, Pentenero M.
Osteonecrosis of the jaw in a patient receiving cabozantinib. Aust
Dent J.
2015;60:528-31. |
|
|||
|
||||
55.
Magremanne M, Lahon M, De Ceulaer J, Reychler H. Unusual
bevacizumab-related complication of an oral infection. J Oral
Maxillofac Surg.
2013;71:53-5. |
|
|||
|
||||
56.
Wolfe RM, Ang DC. Biologic Therapies for Autoimmune and Connective
Tissue Diseases. Immunol Allergy Clin North Am.
2017;37:283-99. |
|
|||
|
||||
57.
Sfikakis PP. The first decade of biologic TNF antagonists in
clinical practice: lessons learned, unresolved issues and future
directions. Curr Dir Autoimmun.
2010;11:180-210. |
|
|||
|
||||
58.
Favia G, Tempesta A, Limongelli L, Crincoli V, Iannone F, Lapadula
G, Maiorano E. A Case of Osteonecrosis of the Jaw in a Patient
with Crohn's Disease Treated with Infliximab. Am J Case Rep.
2017;18:1351-6. |
|
|||
|
||||
59.
Cassoni A, Romeo U, Terenzi V, Della Monaca M, Rajabtork Zadeh O,
Raponi I, et al. Adalimumab: Another Medication Related to
Osteonecrosis of the Jaws?. Case Rep Dent.
2016;2016:2856926. |
|
|||
|
||||
60.
Preidl RH, Ebker T, Raithel M, Wehrhan F, Neukam FW, Stockmann P.
Osteonecrosis of the jaw in a Crohn's disease patient following a
course of Bisphosphonate and Adalimumab therapy: a case report.
BMC Gastroenterol.
2014;14:6. |
|
|||
|
||||
61.
Keribin P, Guerrot D, Jardin F, Moizan H. Osteonecrosis of the Jaw
in a Patient Presenting With Post-Transplantation
Lymphoproliferative Disorder Treated With Rituximab: A Case
Report. J Oral Maxillofac Surg.
2017;75:2599-605. |
|
|||
|
||||
62.
Allegra A, Oteri G, Alonci A, Bacci F, Penna G, Minardi V, et al.
Association of osteonecrosis of the jaws and POEMS syndrome in a
patient assuming rituximab. J Craniomaxillofac Surg.
2014;42:279-82. |
|
|||
|
||||
63.
Davignon JL, Rauwel B, Degboé Y, Constantin A, Boyer JF, Kruglov
A, Cantagrel A. Modulation of T-cell responses by anti-tumor
necrosis factor treatments in rheumatoid arthritis: a review.
Arthritis Res Ther.
2018;20:229. |
|
|||
|
||||
64.
Weinstein RS. Glucocorticoid-induced osteonecrosis. Endocrine.
2012;41:183-90. |
|
|||
|
||||
65.
Powell C, Chang C, Gershwin ME. Current concepts on the
pathogenesis and natural history of steroid-induced osteonecrosis.
Clin Rev Allergy Immunol.
2011;41:102-13. |
|
|||
|
||||
66.
Berti-Couto SA, Vasconcelos AC, Iglesias JE, Figueiredo MA, Salum
FG, Cherubini K. Diabetes mellitus and corticotherapy as risk
factors for alendronate-related osteonecrosis of the jaws: a study
in Wistar rats. Head Neck.
2014;36:84-93. |
|
|||
|
||||
67.
Di Fede O, Bedogni A, Giancola F, Saia G, Bettini G, Toia F, et
al. BRONJ in patients with rheumatoid arthritis: a multicenter
case series. Oral Dis.
2016;22:543-8. |
|
|||
|
||||
68.
Aletaha D, Smolen JS. Diagnosis and Management of Rheumatoid
Arthritis: A Review. JAMA.
2018;320:1360-72. |
|
|||
|
||||
69.
van Dalen EC, van As JW, de Camargo B. Methotrexate for high-grade
osteosarcoma in children and young adults. Cochrane Database Syst
Rev.
2011;5:CD006325. |
|
|||
|
||||
70.
Furukawa S, Oobu K, Moriyama M, Kawano S, Sako S, Hayashida JN, et
al. Oral Methotrexate-related Lymphoproliferative Disease
Presenting with Severe Osteonecrosis of the Jaw: A Case Report and
Literature Review. Intern Med.
2018;57:575-81. |
|
|||
|
||||
71.
Furudate K, Satake A, Narita N, Kobayashi W. Methotrexate-Related
Lymphoproliferative Disorder in Patients With Osteonecrosis of the
Jaw: A 3-Case Report and Literature Review. J Oral Maxillofac
Surg.
2018;76:97-111. |
|
|||
|
||||
72.
Henien M, Carey B, Hullah E, Sproat C, Patel V.
Methotrexate-associated osteonecrosis of the jaw: A report of two
cases. Oral Surg Oral Med Oral Pathol Oral Radiol.
2017;124:e283-7. |
|
|||
|
||||
73.
Wang W, Zhou H, Liu L. Side effects of methotrexate therapy for
rheumatoid arthritis: A systematic review. Eur J Med Chem.
2018;158:502-16. |
|
|||
|
||||
74. Chan ES, Cronstein BN. Mechanisms of action of methotrexate. Bull Hosp Jt Dis. 2013;71:S5-8. |
|
|||
|
||||
75.
Kezic A, Popovic L, Lalic K. mTOR Inhibitor Therapy and Metabolic
Consequences: Where Do We Stand?. Oxid Med Cell Longev.
2018;2018:2640342. |
|
|||
|
||||
76.
Konings IR, Verweij J, Wiemer EA, Sleijfer S. The applicability of
mTOR inhibition in solid tumors. Curr Cancer Drug Targets.
2009;9:439-50. |
|
|||
|
||||
77. Giancola F, Campisi G, Lo Russo L, Muzio LL, Di Fede O. Osteonecrosis of the jaw related to everolimus and bisphosphonate: a unique case report?. Ann Stomatol (Roma). 2013;4:20-1. |
|
|||
|
||||
78.
Omarini C, Filieri ME, Depenni R, Grizzi G, Cascinu S, Piacentini
F. Osteonecrosis of the Jaw in a Breast Cancer Patient Treated
with Everolimus and a Single Dose of Zoledronic Acid. Breast J.
2017;23:610-1. |
|
|||
|
||||
79.
Nifosì AF, Nifosì L, Nifosì G. Osteonecrosis of the Jaw in a
Patient Treated with Denosumab and Temsirolimus. SAJ Case Rep.
2017;4:401. |
|
|||
|
||||
80.
Kim DW, Jung YS, Park HS, Jung HD. Osteonecrosis of the jaw
related to everolimus: a case report. Br J Oral Maxillofac Surg.
2013;51:e302-4. |
|
|||
|
||||
81.
Faes S, Santoro T, Demartines N, Dormond O. Evolving Significance
and Future Relevance of Anti-Angiogenic Activity of mTOR
Inhibitors in Cancer Therapy. Cancers (Basel).
2017;9:E152. |
|
|||
|
||||
82.
Yamamoto D, Tsubota Y, Utsunomiya T, Sueoka N, Ueda A, Endo K, et
al. Osteonecrosis of the jaw associated with everolimus: A case
report. Mol Clin Oncol.
2017;6:255-7. |
|
|||
|
||||
83.
Owosho AA, Scordo M, Yom SK, Randazzo J, Chapman PB, Huryn JM, et
al. Osteonecrosis of the jaw a new complication related to
Ipilimumab. Oral Oncol.
2015;51:e100-1. |
|
|||
|
||||
84.
Nicolatou-Galitis O, Galiti D, Moschogianni M, Sachanas S, Edwards
BJ, Migliorati CA, et al. Osteonecrosis of the jaw in a patient
with acute myeloid leukemia, who received azacitidine. J Cancer
Metasta Treat.
2016;2:220-3. |
|
|||